Theralase has launched new clinical study sites in the U.S. and Canada for its Phase II trial of Ruvidar™ in BCG-unresponsive NMIBC.

A pragmatic clinical trial, Nudge, found that text message reminders did not significantly improve cardiovascular medication adherence compared to usual care.

Callio Therapeutics launches with a substantial $187 million Series A funding round, led by Frazier Life Sciences, to develop innovative multi-payload antibody-drug conjugates for cancer treatment.

Adverum Biotechnologies initiates ARTEMIS, the first-ever registrational intravitreal gene therapy trial for wet AMD, evaluating Ixo-vec against standard aflibercept treatment in 284 patients.

Recent clinical trials demonstrate significant survival benefits with combination immunotherapy approaches in hepatocellular carcinoma, with atezolizumab plus bevacizumab showing superior outcomes compared to traditional sorafenib treatment.

The current healthcare system struggles to provide adequate decision support for community oncologists who treat 85-90% of U.S. cancer patients, highlighting a critical gap in patient care delivery.

The American Academy of Sleep Medicine has released new clinical guidelines for Restless Legs Syndrome treatment, emphasizing iron supplementation and alpha-2-delta ligands as primary interventions.

Lupin has secured a non-exclusive patent license agreement with Takeda Pharmaceutical to commercialize Vonoprazan, a potassium-competitive acid blocker (P-CAB), in India under the brand name Lupivon.

The FDA has blocked approval of flavored e-cigarettes, leading to legal challenges from manufacturers who claim the agency unexpectedly changed its requirements during the application process.

Seismic Therapeutic's S-8484, an engineered IgE protease, demonstrates rapid and sustained degradation of IgE in both plasma and B cell receptors, showing potential for treating allergic diseases.

Petros Pharmaceuticals' proprietary AI-integrated technology achieved success in 30 out of 31 consumer comprehension objectives, meeting FDA's thresholds for potential prescription to over-the-counter drug transitions.

The UC Santa Cruz Colligan Clinical Diagnostic Laboratory has received CLIA certification, enabling them to begin accepting patient samples for specialized RNA analysis in pediatric cancer cases.

Better Choice Company has secured an $8.1 million deal to sell its Halo pet food business in Asia to CZC Company LTD, including $6.5 million in cash and guaranteed royalty payments.

A new study demonstrates that long-acting injectable antipsychotics significantly reduced Young Mania Rating Scale scores from 33.8 to 3.0 over one year in adolescents with bipolar mania or schizoaffective disorder.

Federal Judge Matthew Kacsmaryk in Texas has ruled that Idaho, Kansas, and Missouri can proceed with their legal challenge to restrict federal guidelines for the abortion drug mifepristone.

A comprehensive Swedish population study of 8,672 multiple myeloma patients found they face a five times higher risk of infections compared to healthy controls, with sepsis and pneumonia being the most prevalent.

The Supreme Court will examine the constitutionality of mandated no-cost coverage for PrEP and other preventive services under the Affordable Care Act, following the Braidwood Management Inc. vs Becerra case.

A new study reveals that Duchenne muscular dystrophy patients who maintain walking ability longer show better left ventricular function in adulthood, with loss of ambulation after age 12 reducing heart failure risk five-fold.

Former AstraZeneca head of hit discovery Dr. Garry Pairaudeau joins Exscientia as Chief Technology Officer, bringing 25 years of expertise in AI, machine learning, and drug discovery.

A new Capgemini study reveals 80% of biopharma companies believe connected health products present greater market opportunities than traditional drugs, yet only 20% have moved beyond proof of concept.